Skip to main content
Clinical Trials/NCT06273501
NCT06273501
Enrolling By Invitation
Not Applicable

Preoperative MRI and Magnetometer-guided Intraoperative Sentinel Lymph Node Detection With Superparamagnetic Iron Oxide Nanoparticles (SPIO) in Patients With Vulvar Cancer - a Feasibility Study (POSVUC Pilot)

Sahlgrenska University Hospital, Sweden1 site in 1 country20 target enrollmentMarch 24, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vulvar Cancer
Sponsor
Sahlgrenska University Hospital, Sweden
Enrollment
20
Locations
1
Primary Endpoint
Sentinel lymph node identification
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

The aim of the feasibility study is to evaluate whether SPIO-MRI and a magnetometer could be a potential substitute to the routine dual technique in pre-and intraoperative SLN localization. Secondary, to explore if SPIO-MRI could predict lymph node status in comparison to histopathological analysis.

Detailed Description

Sentinel lymph node (SLN) biopsy is the routine procedure for nodal staging in early vulvar squamous cell carcinoma (VSCC) in the absence of clinical signs of lymph node metastasis. The gold standard technique for identifying SLN utilizes Technetium (Tc99m) lymphoscintigraphy and blue dye. An alternative method has emerged using superparamagnetic iron-oxide (SPIO) and magnetic resonance imaging (MRI). This study aims to enroll 20 VSCC patients scheduled for the SLN procedure. Determination of the minimal dosage of SPIO required to avoid excessive MRI artifacts while still identifying the SLN. Intraoperative SLN detection with a magnetometer will be compared with the gold standard gamma probe. As secondary objective, in addition to determining the SNL, MRI analysis of the nodal status will be evaluated for potential metastasis and compared to histopathological results.

Registry
clinicaltrials.gov
Start Date
March 24, 2022
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Sahlgrenska University Hospital, Sweden
Responsible Party
Principal Investigator
Principal Investigator

Katja Stenström Bohlin

Principal Investigator

Sahlgrenska University Hospital, Sweden

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed primary VSCC \<4 cm, candidates for surgery with SLNB Age above 18
  • Signed and dated written consent before the start of specific protocol procedures.
  • ECOG performance status 0-2

Exclusion Criteria

  • Contraindications for MRI such as electronic implants or severe claustrophobia
  • Hip replacement
  • Iron overload disease
  • Known hypersensitivity to iron or dextran compounds
  • Inability to understand given information and give informed consent or undergo study procedure

Outcomes

Primary Outcomes

Sentinel lymph node identification

Time Frame: Within 30 days after SPIO injection.

The number of lymph nodes identified preoperatively with SPIO-enhanced MRI and intraoperatively with a magnetometer compared to Technetium-99m scintigraphy and blue dye.

Study Sites (1)

Loading locations...

Similar Trials